Last reviewed · How we verify
NCT03290508
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
trial testing Prolaris Testing in Prostate Cancer in 524 participants. Terminated before completion.
14 January 2022
Quick facts
| Lead sponsor | Myriad Genetic Laboratories, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 524 |
| Start date | 14 September 2017 |
| Primary completion | 14 January 2022 |
| Estimated completion | 14 January 2022 |
| Sites | 34 locations across United States |
Drugs / interventions tested
- Prolaris Testing
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Myriad Genetic Laboratories, Inc.
Who can join
65 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03290508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Myriad Genetic Laboratories, Inc. trials
Trials by the same sponsor.
- NCT04016935 — EndoPredict® Extended Endocrine Trial (EXET) · terminated
- NCT04015102 — A Registry for Hereditary Cancer Risk Assessment and Genetic Testing · completed
- NCT03511235 — Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing · completed
- NCT03081455 — Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes · completed
- NCT03067389 — Combined Breast Cancer Risk Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03290508 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Myriad Genetic Laboratories, Inc.
- Last refreshed: 23 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03290508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing